PP
DNTH icon

PDT Partners’s Dianthus Therapeutics DNTH Stock Holding History

PDT Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,575
Closed -$246K – 805
2021
Q2 		$246K Buy
1,575
+410
+35% +$75.3K 0.02% 656
2021
Q1 		$221K Sell
1,165
-872
-43% -$147K 0.02% 685
2020
Q4 		$256K Buy
+2,037
New +$231K 0.02% 577

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PDT Partners's DNTH Position: Q3 2021 in Review

PDT Partners sold out of Dianthus Therapeutics (DNTH) in Q3 2021, closing a stake of 1,575 shares — an estimated $246K sold.

PDT Partners first reported a position in DNTH in Q4 2020 and held it in 3 quarters. The position peaked at $256K in Q4 2020. 93 funds tracked by Wall St. Rank hold DNTH as of Q3 2021.

  • PDT Partners reported no remaining Dianthus Therapeutics position as of Q3 2021 after selling out during the quarter.
  • PDT Partners sold 1,575 Dianthus Therapeutics shares in Q3 2021, an estimated $246K.
  • PDT Partners first reported a position in Dianthus Therapeutics in Q4 2020 and held it in 3 quarters.
  • PDT Partners's Dianthus Therapeutics position peaked at $256K in Q4 2020.
  • 93 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2021.

Based on PDT Partners's 13F filing for Q3 2021, filed 15 Nov 2021.